32
Participants
Start Date
January 31, 1999
Primary Completion Date
November 30, 2000
Study Completion Date
November 30, 2009
r-metHuSCF and Filgrastim
Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
r-metHuSCF and Filgrastim
Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
Chemotherapy plus Filgrastim
Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
Rigshospitalet, Copenhagen
Aalborg Hospital, Aalborg
Herlev University Hospital, Copenhagen
University Hospital Helsinki, Helsinki
University Hospital Turku, Turku
Radiumhospitalet, Oslo
University Hospital Linköping, Linköping
University Hospital Umeå, Umeå
Collaborators (1)
Herlev Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Helsinki University Central Hospital
OTHER
Turku University Hospital
OTHER_GOV
University Hospital, Linkoeping
OTHER
Umeå University
OTHER
Oslo University Hospital
OTHER
Nordic Lymphoma Group
NETWORK
Amgen
INDUSTRY
Aalborg University Hospital
OTHER